01—Abstract
Summary
Summary of the 10-K filed February 21, 2013. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. reported its 2012 annual results, highlighting significant progress in its continuous glucose monitoring (CGM) technology.
The company received FDA approval for its fourth-generation G4 PLATINUM system in October 2012, a key advancement designed for improved accuracy, a sleeker receiver, and better sensor performance. This new system is poised to be a primary revenue driver, with marketing efforts shifting from the older SEVEN PLUS model. The company also expanded its reach by securing CE Mark approval for the G4 system in Europe and other international markets.
Financially, DexCom saw a substantial increase in product revenue, reaching $93.0 milliona in 2012, driven by higher sales volumes and the introduction of the G4 PLATINUM. However, the company continued to incur net losses, with a reported net loss of $54.5 million for the year.
Despite ongoing losses, the company's cash position remained stable, and it raised capital through equity offerings. The company is focused on further development, including seeking pediatric indications for its G4 PLATINUM system, and expanding market access through strategic partnerships and reimbursement efforts.
02—Key points
Key Highlights
- Launch of the G4 PLATINUM system in the U.S. in Q4 2012, a key next-generation product.
- FDA approval for the G4 PLATINUM system in October 2012, enhancing product offerings.
- Product revenue increased by 41% to $93.0 million in 2012, driven by increased sales volume.
- Secured CE Mark approval for the G4 system in Europe and other international markets, expanding global reach.
- Acquisition of SweetSpot Diabetes Care in March 2012 to bolster data management and analytics capabilities.
- Continued investment in R&D, with R&D expenses increasing to $39.5 million in 2012.
- Secured a $35 million loan facility in November 2012 to support operations and growth.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2012, Dexcom Inc lost $0.55.
- Revenue$99.9M100.0%
- Cost of revenue−$53.3M53.4%
- Gross profit$46.6M46.6%
- Operating costs−$102.3M102.4%
- Operating income−$55.7M55.8%
- Interest, other & tax$1.2M1.2%
- Net income−$54.5M54.6%
04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 21, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $99.90M$76.30M | +30.9% |
| Cost of Revenue | $53.30M$40.40M | +31.9% |
| Gross Profit | $46.60M$35.90M | +29.8% |
| R&D Expenses | $38.30M$29.60M | +29.4% |
| SG&A Expenses | $64.00M$51.10M | +25.2% |
| Operating Expenses | $102.30M$80.70M | +26.8% |
| Operating Income | -$55.70M-$44.80M | −24.3% |
| Interest Expense | $200K$0 | — |
| Net Income | -$54.50M-$44.70M | −21.9% |
| EPS (Basic) | $-0.20$-0.17 | −16.2% |
| Shares Outstanding (Basic) | 274.80M262.40M | +4.7% |
05—Questions
Frequently Asked Questions
What is DexCom's primary product line?
DexCom's primary product line consists of continuous glucose monitoring (CGM) systems for ambulatory use by individuals with diabetes. Their key products include the SEVEN PLUS and the recently launched G4 PLATINUM systems.
What were the key financial results for 2012?
In 2012, DexCom reported product revenue of $93.0 million, a significant increase from $65.9 million in 2011. However, the company continued to experience net losses, with a net loss of $54.5 million for the year, compared to a net loss of $44.7 million in 2011. The company's cash and cash equivalents stood at $48.7 million at year-end 2012.
What are the main risks facing DexCom?
Key risks for DexCom include the need for market acceptance of its products by patients and physicians, reliance on third-party payor reimbursement (with no national Medicare coverage decision yet), intense competition from established medical device companies, potential patent litigation (notably with Abbott), and the ongoing need for capital to fund research, development, and commercialization efforts, given the company's history of net losses.
What are DexCom's future development plans?
DexCom plans to develop future generations of its technology for improved performance and convenience, with a focus on enabling intelligent insulin administration and developing networked platforms with open architecture. They are also seeking FDA approval for a pediatric indication for the G4 PLATINUM system and intend to seek approval for a pregnancy indication in the future.
06—Continue